ARMATA PHARMACEUTICALS, INC. (ARMP) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 5.72M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -40.70M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $5.72M | $-40.70M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $2.90M | $-37.23M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $2.61M | $-36.63M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $2.33M | $-33.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $2.38M | $-35.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $3.14M | $-40.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $2.89M | $-42.44M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | $2.73M | $-41.48M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $1.69M | $-42.06M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $615.00K | $-39.77M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $938.00K | $-40.89M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $1.56M | $-41.64M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $2.78M | $-39.93M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $3.47M | $-39.52M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $3.10M | $-36.95M | $0.00 | (m) | (m) | (m) | Reported |
| 2022-09-30 | (m) | (m) | $2.95M | $-32.67M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | $2.58M | $-30.19M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | $2.53M | $-27.16M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $2.88M | $-23.82M | $64.00K | (m) | (m) | -372.22× | Reported |
| 2021-09-30 | (m) | (m) | $3.08M | $-24.23M | $241.00K | (m) | (m) | -100.53× | Reported |
| 2021-06-30 | (m) | (m) | $3.27M | $-23.71M | $389.00K | (m) | (m) | -60.94× | Reported |
| 2021-03-31 | (m) | (m) | $3.27M | $-22.10M | $531.00K | (m) | (m) | -41.62× | Reported |
| 2020-12-31 | (m) | (m) | $3.48M | $-21.59M | $628.00K | (m) | (m) | -34.37× | Reported |
| 2020-09-30 | (m) | (m) | $3.66M | $-19.51M | $656.00K | (m) | (m) | -29.74× | Reported |
| 2020-06-30 | (m) | (m) | $5.50M | $-20.66M | $696.00K | (m) | (m) | -29.69× | Reported |
| 2020-03-31 | (m) | (m) | $5.22M | $-21.23M | $784.00K | (m) | (m) | -27.08× | Reported |
| 2019-12-31 | $9.82M | (m) | $4.27M | $-19.75M | $931.00K | (m) | (m) | -21.22× | Reported |
| 2019-09-30 | (m) | (m) | $3.65M | $-13.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | $1.16M | $-8.69M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $4.92M | (m) | $455.00K | $-13.07M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.89M | (m) | $478.00K | $-12.52M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $4.61M | (m) | $498.00K | $-10.11M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $3.42M | (m) | $476.00K | $-9.22M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $2.85M | (m) | $651.00K | $-15.85M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $2.88M | (m) | $700.00K | $-16.16M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | $865.00K | $-25.66M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $5.08M | (m) | $1.10M | $-28.32M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $5.19M | (m) | $1.35M | $-22.22M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $5.68M | (m) | $2.00M | $-23.38M | $6.00K | (m) | (m) | -3896.33× | Reported |
| 2016-09-30 | $6.09M | (m) | $1.92M | $-14.45M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $5.16M | (m) | $1.74M | $-13.47M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $5.00M | (m) | $1.24M | $-12.48M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $3.99M | (m) | $479.00K | $-10.23M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $3.89M | (m) | $310.00K | $-9.88M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $4.96M | (m) | $412.00K | $-12.69M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $5.77M | (m) | $593.00K | $-13.84M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $5.80M | (m) | $775.00K | $-14.11M | $0.00 | (m) | (m) | (m) | Reported |
| 2014-09-30 | $5.81M | (m) | $990.00K | $-13.90M | $0.00 | (m) | (m) | (m) | Reported |
| 2014-06-30 | $5.11M | (m) | $1.01M | $-11.28M | $9.00K | (m) | (m) | -1253.11× | Reported |
| 2014-03-31 | $6.96M | (m) | $1.54M | $-13.81M | $137.00K | (m) | (m) | -100.80× | Reported |
| 2013-12-31 | $6.50M | (m) | $1.44M | $-12.44M | $233.00K | (m) | (m) | -53.37× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |